1. Title (length 26):
Aspirin Correlates/Trends

2. Writing Group (list individual with lead responsibility first):
(lead) Shahar               Chambliss
Folsom                    Hutchinson
Romm                         Heiss

3. Timeline:
Analysis - through Winter 1993
Draft - Spring 1993

4. Rationale:
Considerable data from both observational studies and clinical trials suggest that regular aspirin use has a
preventive role in cardiovascular diseases. Being a non-prescribed medication, patterns of aspirin use in the
general population are likely to reflect both medical practice and self-initiated usage. Surprisingly, few data
are available regarding determinants of aspirin use or trends in recent years. The findings of the Physicians'
Health Study (which likely had substantial impact on aspirin use) were first published in January 1988, about
the time that one-third of the ARIC cohort completed the baseline examination.

5. Main Hypothesis:
The manuscript will examine demographic, socioeconomic, and clinical correlates of aspirin use in blacks and
whites in visit 1 and again in visit 2. It is hypothesized that aspirin use is more frequent among subjects in
higher SES and among those with higher CVD risk scores. The second part of the manuscript will examine
trends in use in visit 1 before and after January 1988 and again between visit 1 as a whole and visit 2. It is
hypothesized that a dramatic increase in aspirin use occurred during visit 1 and a moderate increase
continued through visit 2.

6. Data (variables, time window, source, inclusions/exclusions):
Both visit 1 and visit 2 data: medications; demographic and socioeconomic variables; CVD risk factors
(cholesterol, smoking, diabetes, family history, etc.); prevalent CVD variables (symptomatic CHD,
intermittent claudication, history of stroke).
Aspirin (or aspirin containing medications, excluding cold meds) will be identified as MTC codes 641000
and 641099 (salicylates). Generic names (GNAME) will also be checked to assure completeness of the
data.